human milk oligosaccharide

What a human milk oligosaccharide is

HMOs share a lactose unit at the reducing end, but extensions and the addition of fucose or sialic acid create many distinct molecules. More than 200 HMO structures have been described in human milk. “HMO” therefore identifies a family; it does not provide a complete chemical identity for purchasing or formulation.

A commercial specification should name the exact HMO or defined mixture. That identity determines the formula, molecular weight, CAS information where applicable, assay method, impurity profile, and regulatory review.

Structure determines functional relevance

HMO research describes several complementary biological pathways, and each depends on molecular structure. Some HMOs are selectively used by particular gut microorganisms, including certain Bifidobacterium strains. This selective use can influence microbial ecology and the metabolites produced during fermentation.

Some HMO structures can also interact with microbial adhesion targets as soluble decoys. The relevant binding behavior depends on the terminal sugars and linkages present, so evidence for one HMO cannot be transferred automatically to another.

Research also examines interactions between HMOs, intestinal epithelial processes, and immune signaling. Evidence remains structure-specific: a result associated with one molecule, dose, or population does not establish the same result for the entire HMO family.

Explore Sgnutri's HMO ingredient

Human milk oligosaccharides (HMOs)

A white to off-white powder or crystalline ingredient listing for buyers evaluating HMOs. Because HMOs are a group of structurally distinct compounds, the exact identity and product-specific specification should be confirmed with the quotation.

• Chemical formulaVaries by HMO structure
• CAS numberNo single CAS number applies to the HMO group
• Molecular weightVaries by oligosaccharide
• AppearanceWhite to off-white powder or crystalline form
• Thermal behaviorDecomposes before melting

Ask About This HMOView Product Details

2'-FL/HMO specification, quality, and handling

The reference specification supplied for 2'-fucosyllactose (2'-FL/HMO) lists the following composition and quality limits. These values describe the supplied 2'-FL/HMO specification; they are not a universal specification for every HMO structure.

Composition and physical criteria

Contaminant and microbiological criteria

This 2'-FL/HMO is packed in 20 kg (44.1 lb) food-grade aluminum-foil composite bags. Its stated shelf life is 24 months under dry, clean, and ventilated storage conditions. Keep the bag closed and protect the powder from moisture during warehousing and sampling.

The current technical data sheet and batch certificate of analysis provide the applicable release criteria and results for an order.

Choose an HMO by structure, evidence, and end use

The intended function narrows the relevant evidence, but the molecule named in that evidence still controls the ingredient choice. A study on 2'-FL, for example, does not establish an equivalent outcome for LNnT or a sialylated HMO. Consumer group, serving level, and final product format further determine whether that evidence fits a formulation.

Commercial ingredients with the same HMO name are not automatically interchangeable. Manufacturing process, purity, related sugars, microbiological limits, and stability can affect regulatory support, processing behavior, analytical release, and label review. A substitute should therefore be assessed against the finished-product specification and substantiation, not only the name on a catalog page.

In the United States, safety and regulatory support is tied to the specific substance, manufacturing description, specifications, food categories, use levels, and population described in the supporting record. Infant formula, foods for young children, dietary supplements, and general foods do not share one universal use framework. The FDA's GRAS Notice Inventory is a useful starting point for reviewing these conditions; a notice concerning another source or process does not automatically cover a quoted ingredient.

Ask Sgnutri to match the offered HMO and its technical documentation to the final product, consumer group, target use level, and market before a formulation is locked.

Frequently asked questions